Key facts
- Autoimmunity BioSolutions’s last known valuation is $6.0M (Nov 2024).
- It has raised $2.2M; the latest was Angel (individual) in Sep 2025.
- Notable investors include Alexandria Venture Investments, Independent Capital Partners, Eos BioInnovation, National Institutes of Neurological Disorders and Stroke, Newsight Tech Angels.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Autoimmunity BioSolutions
- ·The full record, as it builds
Funding rounds
No funding rounds for Autoimmunity BioSolutions are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Autoimmunity BioSolutions
Developer of diagnostic and therapeutic solutions created for the treatment of multiple sclerosis. The company deploys a therapeutic platform for autoimmune and other related diseases that can be addressed by modulating the patient's immune system, enabling patients to correct their immune system with targeted therapies.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2016
- Website
- abstherapeutics.com/
- Ownership
- Privately Held (backing)
Autoimmunity BioSolutions doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Autoimmunity BioSolutions shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Autoimmunity BioSolutions in its N-PORT filings yet. We sweep new filings monthly.